Genetic determinants of variability in warfarin response after the dose-titration phase.

ABSTRACT:

Objectives

Genetic factors contribute considerably toward variability in warfarin dose requirements and are important in the dose-titration phase; their effects on the stability of anticoagulation later in therapy are not known.

Methods

Using deidentified electronic medical records linked to a DNA-biobank, we studied 140 African-Americans and 943 European-Americans after the warfarin dose-titration phase. We genotyped 12 single nucleotide polymorphisms in genes (CYP2C9, VKORC1, CYP4F2, GGCX, EPHX1, CALU) associated with altered warfarin dose requirements and tested their associations with international normalized ratio variability (INRVAR) and percent time in therapeutic range in European-Americans and African-Americans.

Results

One allele copy of rs2108622 in CYP4F2

SUBMITTER: Iwuchukwu OF 

PROVIDER: S-EPMC5300764 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature